公开(公告)号：US08461114B2

公开(公告)日：2013-06-11

申请号：US12780065

申请日：2010-05-14

申请人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

发明人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

IPC分类号： A61K38/00

CPC分类号： C07K14/4702 ,  C07K16/32 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/14

摘要： Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.

摘要翻译： 调节ErbB2和Erbin之间的相互作用是治疗ErbB2介导的疾病的一种或多种症状的有效方法。 已经发现Erbin在体内稳定ErbB2并且抑制Erbin和ErbB2之间异源二聚体的形成相对于对照水平降低或抑制ErbB2的生物学活性。 降低ErbB2的生物活性可用于治疗以ErbB2的过表达或失调为特征的病症。 这些病症包括但不限于乳腺癌和前列腺癌。 或者，促进或增强Erbin与ErbB2相互作用的Erbin激动剂可用于治疗某些神经障碍。 还发现Erbin在周围神经系统神经元的髓鞘形成中起作用。

公开(公告)号：US20100291077A1

公开(公告)日：2010-11-18

申请号：US12780065

申请日：2010-05-14

申请人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

发明人： Lin Mei ,  Yanmei Tao ,  Wen-Chen Xiong

IPC分类号： A61K39/395 ,  C12N5/02 ,  A61P35/00

CPC分类号： C07K14/4702 ,  C07K16/32 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/14

摘要： Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.

摘要翻译： 调节ErbB2和Erbin之间的相互作用是治疗ErbB2介导的疾病的一种或多种症状的有效方法。 已经发现Erbin在体内稳定ErbB2并且抑制Erbin和ErbB2之间异源二聚体的形成相对于对照水平降低或抑制ErbB2的生物学活性。 降低ErbB2的生物活性可用于治疗以ErbB2的过表达或失调为特征的病症。 这些病症包括但不限于乳腺癌和前列腺癌。 或者，促进或增强Erbin与ErbB2相互作用的Erbin激动剂可用于治疗某些神经障碍。 还发现Erbin在周围神经系统神经元的髓鞘形成中起作用。